Citius Pharmaceuticals Cost of Revenue 2011-2026 | CTXR

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Citius Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	75 K	50 K	45 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
75 K	45 K	56.7 K

Quarterly Cost of Revenue Citius Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
789 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
789 K	789 K	789 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
ADMA Biologics ADMA	217 M	$ 15.36	-2.17 %	$ 3.66 B	USA
Cellectis S.A. CLLS	31.4 M	$ 3.53	-3.54 %	$ 116 M	France
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Nymox Pharmaceutical Corporation NYMX	4 K	-	-19.68 %	$ 18.4 M	Canada
Aptorum Group Limited APM	421 K	$ 0.79	-1.15 %	$ 4.31 M	China
China SXT Pharmaceuticals SXTC	1.37 M	$ 2.01	-1.36 %	$ 2.86 M	China
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Anika Therapeutics ANIK	63.6 M	$ 14.05	-1.44 %	$ 206 M	USA
ANI Pharmaceuticals ANIP	250 M	$ 74.36	-1.64 %	$ 1.44 B	USA
AVEO Pharmaceuticals AVEO	4.74 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	47.5 M	$ 162.43	0.6 %	$ 8.08 B	USA
BioCryst Pharmaceuticals BCRX	12.3 M	$ 8.49	-0.18 %	$ 1.75 B	USA
BridgeBio Pharma BBIO	21 M	$ 65.66	-0.78 %	$ 12.6 B	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
BioDelivery Sciences International BDSI	23.4 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	70.7 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	436 K	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	24.8 M	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
BioMarin Pharmaceutical BMRN	717 M	$ 61.3	1.21 %	$ 11.8 B	USA